These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 11053058)

  • 21. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes.
    Burger D; Begué-Pastor N; Benavent S; Gruaz L; Kaufmann MT; Chicheportiche R; Dayer JM
    Rheumatology (Oxford); 2003 Jan; 42(1):89-96. PubMed ID: 12509619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.
    Sanders S; Harisdangkul V
    Am J Med Sci; 2002 Apr; 323(4):190-3. PubMed ID: 12003373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
    van Roon EN; Jansen TL; van de Laar MA; Janssen M; Yska JP; Keuper R; Houtman PM; Brouwers JR
    Ann Rheum Dis; 2005 Apr; 64(4):569-74. PubMed ID: 15345501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases.
    Wang J; Sun J; Hu J; Wang C; Prinz RA; Peng D; Liu X; Xu X
    FASEB J; 2020 Aug; 34(8):10132-10145. PubMed ID: 32598086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
    Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
    Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leflunomide in clinical practice.
    Pinto P; Dougados M
    Acta Reumatol Port; 2006; 31(3):215-24. PubMed ID: 17094333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide--mechanisms independent of pyrimidine depletion.
    Korn T; Magnus T; Toyka K; Jung S
    J Leukoc Biol; 2004 Nov; 76(5):950-60. PubMed ID: 15328336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
    Sawamukai N; Saito K; Yamaoka K; Nakayamada S; Ra C; Tanaka Y
    J Immunol; 2007 Nov; 179(10):6479-84. PubMed ID: 17982036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.
    Cherwinski HM; Cohn RG; Cheung P; Webster DJ; Xu YZ; Caulfield JP; Young JM; Nakano G; Ransom JT
    J Pharmacol Exp Ther; 1995 Nov; 275(2):1043-9. PubMed ID: 7473131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of anti-CD3 antibody-induced mouse T cell activation by pentoxifylline in combination with rapamycin or A77 1726 (leflunomide).
    Richard M; Hoskin DW
    Int J Immunopharmacol; 1998; 20(4-5):241-52. PubMed ID: 9730259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sex hormones modulate the effects of Leflunomide on cytokine production by cultures of differentiated monocyte/macrophages and synovial macrophages from rheumatoid arthritis patients.
    Cutolo M; Montagna P; Brizzolara R; Sulli A; Seriolo B; Villaggio B; Triolo P; Clerico P; Soldano S
    J Autoimmun; 2009; 32(3-4):254-60. PubMed ID: 19324522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture.
    Ju DW; Zheng QY; Wang HB; Fang J
    Zhongguo Yao Li Xue Bao; 1994 May; 15(3):223-6. PubMed ID: 7976375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes.
    Palmer G; Burger D; Mezin F; Magne D; Gabay C; Dayer JM; Guerne PA
    Arthritis Res Ther; 2004; 6(3):R181-9. PubMed ID: 15142263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Restriction of de novo pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation.
    Dimitrova P; Skapenko A; Herrmann ML; Schleyerbach R; Kalden JR; Schulze-Koops H
    J Immunol; 2002 Sep; 169(6):3392-9. PubMed ID: 12218161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leflunomide and malononitriloamides.
    Silva HT; Morris RE
    Expert Opin Investig Drugs; 1997 Jan; 6(1):51-64. PubMed ID: 15989561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.
    Kraan MC; Smeets TJ; van Loon MJ; Breedveld FC; Dijkmans BA; Tak PP
    Ann Rheum Dis; 2004 Sep; 63(9):1056-61. PubMed ID: 15115713
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis.
    Kremer JM
    Semin Arthritis Rheum; 1999 Aug; 29(1):14-26. PubMed ID: 10468411
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis.
    Alldred A; Emery P
    Expert Opin Pharmacother; 2001 Jan; 2(1):125-37. PubMed ID: 11336574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there a rationale to using leflunomide in early rheumatoid arthritis?
    Dayer JM; Cutolo M
    Clin Exp Rheumatol; 2005; 23(3):404-12. PubMed ID: 15971434
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-dependent enhancing and inhibitory effects of A77 1726 (leflunomide) on cytotoxic T lymphocyte induction.
    Hoskin DW; Taylor RM; Makrigiannis AP; James H; Lee TD
    Int J Immunopharmacol; 1998 Sep; 20(9):505-13. PubMed ID: 9818794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.